Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib

Cancer Biology and Therapy

Volumn 11, Issue 3, 2011, Pages 330-336

  Lee, Sin Ae ^a   Lee, Mi Sook ^a   Ryu, Hyung Won ^b   Kwak, Tae Kyoung ^a   Kim, Hyeonjung ^a   Kang, Minkyung ^a   Jung, Oisun ^a   Kim, Hyun Jeong ^a   Park, Ki Hun ^b   Lee, Jung Weon ^a  

^a Seoul National University   (South Korea)

^b Gyeongsang National University   (South Korea)

Author keywords

Anti tumorigenic reagent; Contact inhibition; Liver carcinoma; Sorafenib; TM4SF5

Indexed keywords

4' (P TOLUENESULFONYLAMIDO) 4 HYDROXYCHALCONE; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; SORAFENIB; TRANSMEMBRANE 4 L SIX FAMILY MEMBER 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHALCONE; DRUG DISCOVERY; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, NUDE; PYRIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951534453     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.3.14099     Document Type: Article

References (15)

1. El-Serag HB. Translational research: the study of community effectiveness in digestive and liver disorders. Gastroenterology 2007; 132:8-10. (Pubitemid 46108760)
2. Hui KM. Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications. Cancer Lett 2009; 286:96-102.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6:674-87. (Pubitemid 44286000)
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
6. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109. (Pubitemid 39331023)
7. Chang YS, Adnane J, Trail PA, Wilkie D, McNabola A, Rong H, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59:561-74. (Pubitemid 46295136)
8. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-6.
9. Wright MD, Ni J, Rudy GB. The L6 membrane proteins - a new four-transmembrane superfamily. Protein Sci 2000; 9:1594-600. (Pubitemid 30659198)
10. Lee SA, Kim TY, Kwak TK, Kim H, Kim S, Lee HJ, et al. Transmembrane 4 L six family member 5 (TM4SF5) enhances migration and invasion of hepatocytes for effective metastasis. J Cell Biochem 2010; 111:59-66.
11. Lee SA, Lee SY, Cho IH, et al. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest 2008; 118:1354-66.
12. Choi S, Lee SA, Kwak TK, Oh MA, Kang ES, Kim YB, et al. Cooperation between integrin α5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood 2009; 113:1845-55.
13. Lee SA, Kim YM, Kwak TK, Kim HJ, Kim S, Ko W, et al. The extracellular loop 2 of TM4SF5 inhibits integrin α2 on hepatocytes under collagen type I environment. Carcinogenesis 2009; 30:1872-9.
14. Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ, Kwak TK, et al. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 2009; 49:1316-25.
15. Seo WD, Kim JH, Kang JE, Ryu HW, Curtis-Long MJ, Lee HS, et al. Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors. Bioorg Med Chem Lett 2005; 15:5514-6. (Pubitemid 41562981)